DelveInsight’s “Type 1 Diabetes Treatment Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the market dynamics, competitive landscape, key growth drivers, emerging therapies, and future opportunities shaping the global Type 1 Diabetes industry.
Interested to know which Type 1 Diabetes therapies will capture the highest market share?
Download the report to understand the latest Type 1 Diabetes market trends and forecasts – https://www.delveinsight.com/report-store/type-1-diabetes-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr
Key Takeaways from the Type 1 Diabetes Market Report
The global Type 1 Diabetes market across the 7MM is anticipated to grow at a significant CAGR during the forecast period (2023–2034).
Type 1 Diabetes is an autoimmune disease that leads to the destruction of insulin-producing pancreatic beta cells.
The United States accounts for the largest Type 1 Diabetes market share (~89%) in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
In 2023, nearly half of the reported cases of Type 1 Diabetes in the United States were among individuals aged 40 and above.
Among the seven major markets, during the forecast period (2024–2034), TZIELD (teplizumab) is expected to garner the highest market share followed by REMD-477.
Insulin therapies remain the mainstay of treatment. Approved Type 1 Diabetes drugs include TZIELD (Sanofi), TOUJEO/LANTUS XR (Sanofi), LYUMJEV (Eli Lilly and Company), FIASP (Novo Nordisk), and others.
In March 2023, Sanofi announced the acquisition of Provention Bio, adding TZIELD – the first disease-modifying treatment designed to delay Stage 3 T1D – to its portfolio.
In March 2024, Novo Nordisk received a positive opinion from the EMA’s CHMP endorsing marketing authorization for AWIQLI (once-weekly basal insulin icodec) for treating diabetes in adults.
Several promising therapies are under development including ladarixin (Dompé Farmaceutici), basal insulin-fc (Eli Lilly and Company), insulin icodec (Novo Nordisk), and DIAMYD (Diamyd Medical), among others.
Leading Type 1 Diabetes companies include Eli Lilly and Company, AstraZeneca, Novo Nordisk, Zealand Pharma, Vertex Pharmaceuticals, REMD Biotherapeutics, Diamyd Medical, and others.
Gain a competitive edge in the Type 1 Diabetes Market by exploring our in-depth analysis @ Type 1 Diabetes Market Report – https://www.delveinsight.com/report-store/type-1-diabetes-market
Type 1 Diabetes Market Overview
The global Type 1 Diabetes market is evolving rapidly as healthcare systems increasingly invest in disease-modifying and precision-driven therapeutic approaches. Unlike conventional insulin management, emerging therapies seek to address the underlying autoimmune pathology, delay disease progression, and preserve residual beta cell function.
Growing prevalence of T1DM worldwide, combined with increasing demand for more effective and convenient treatment options, continues to fuel market growth. The integration of novel drug classes including anti-CD3 monoclonal antibodies, IL-8 inhibitors, weekly insulin formulations, and allogeneic pancreatic islets has significantly expanded the therapeutic landscape for Type 1 Diabetes. The expanding pipeline of advanced disease-modifying therapies is contributing meaningfully to the adoption of next-generation treatment approaches across the seven major markets.
Factors Driving the Growth of the Type 1 Diabetes MarketRising Global Prevalence of Type 1 Diabetes
The increasing prevalence of Type 1 Diabetes worldwide remains one of the primary growth drivers for the market. Among the 7MM, the United States represented the majority of Type 1 Diabetes diagnosed prevalent cases, comprising approximately 56% of total T1DM cases. Rising case counts across all age groups have created substantial demand for both established insulin therapies and novel disease-modifying treatments.
Advancement of Disease-Modifying Therapies
The approval of TZIELD (teplizumab) as the first disease-modifying therapy to delay Stage 3 Type 1 Diabetes marks a landmark shift in the treatment paradigm. This has accelerated interest and investment in therapies that target the autoimmune mechanisms underlying T1DM, including IL-8 inhibitors, diabetes vaccines, and allogeneic pancreatic islet platforms.
Innovation in Insulin Formulations
Rapid advancements in insulin delivery, including the development of once-weekly basal insulin analogs such as insulin icodec (AWIQLI) and basal insulin-FC (LY3209590), are addressing the limitations of current multiple daily injection regimens. These innovations are expected to improve patient adherence, glycemic control, and overall quality of life.
Growing Focus on Personalized Diabetes Management
The increasing focus on individualized treatment approaches is driving demand for therapies with differentiated mechanisms of action. Treatments targeting beta cell preservation, antigen-specific immune tolerance, and adjunct therapy to insulin are broadening the clinical options available to T1DM patients across different age groups and disease stages.
New Type 1 Diabetes Companies Entering the Market
The growing therapeutic and commercial attractiveness of the T1DM sector continues to encourage new companies to enter the market, supported by increasing investments, novel clinical programs, and expanding regulatory pathways for disease-modifying interventions.
Type 1 Diabetes Market Segment Analysis
The Type 1 Diabetes treatment market is segmented by therapy class, including insulin therapies and emerging disease-modifying agents. Insulin therapies – including rapid-acting, long-acting, and the emerging category of once-weekly basal insulins – currently represent the mainstay of treatment revenue. In 2023, insulin aspart generated the highest Type 1 Diabetes drugs market revenue, followed by insulin glargine.
Emerging disease-modifying therapies, led by TZIELD, are expected to drive incremental market growth during the forecast period as they address previously unmet needs in delaying disease onset and preserving beta cell function.
Type 1 Diabetes Market Regional AnalysisNorth America is Expected to Dominate the Overall Type 1 Diabetes Market
North America is anticipated to maintain the largest market share owing to high T1DM prevalence, strong endocrinology research infrastructure, favorable regulatory policies, and widespread clinical adoption of both established and novel therapeutic approaches.
The United States accounted for approximately 89.3% of the total 7MM Type 1 Diabetes treatment market size in 2023, supported by high healthcare spending, strong reimbursement frameworks, and increasing regulatory support for next-generation T1DM therapies. Continued investments in disease-modifying treatments and beta cell preservation strategies are expected to sustain regional leadership.
Among EU4 countries and the United Kingdom, Germany accounted for the highest Type 1 Diabetes diagnosed prevalent cases – approximately 30% of total EU4 and UK cases – and held the highest market size of T1DM in 2023 among these markets. In Germany, around 230,000 patients with T1DM were reported to be aged over 40 years in 2023.
Japan and other markets across the 7MM are also projected to witness steady growth driven by rising T1DM prevalence, expanding patient access, and increasing availability of advanced treatment options during the forecast period.
Type 1 Diabetes Key Companies
Type 1 Diabetes companies include:
Eli Lilly and Company
Landos Biopharma
Diamyd Medical
Gan & Lee Pharmaceuticals
Zealand Pharma
Kamada
AstraZeneca
Novo Nordisk
Provention Bio
Histogen
Vertex Pharmaceuticals
Panbela Therapeutics
Arecor Therapeutics
Bioprojet
Novartis
ImCyse
Adocia
Anelixis Therapeutics
Tolerion
TikoMed
Avotres
REMD BiotherapeuticsAnd Others.
Download the report to understand which factors are driving Type 1 Diabetes Market Trends – https://www.delveinsight.com/sample-request/type-1-diabetes-market
Latest Highlights from the Type 1 Diabetes Market
In September 2025, Lexicon Pharmaceuticals submitted new clinical data to the FDA supporting a potential resubmission of Zynquista® (sotagliflozin), an oral SGLT1/SGLT2 inhibitor for Type 1 Diabetes, following FDA concerns about diabetic ketoacidosis risk raised in a 2024 complete response letter.
In April 2025, DexCom announced FDA clearance of the Dexcom G7 15-Day Continuous Glucose Monitoring (CGM) System for adults with diabetes in the U.S., featuring an overall MARD of 8.0% and extended wear capability.
In February 2025, NLS Pharmaceutics, Kadimastem, and iTolerance announced results of a Type B pre-IND meeting with the FDA on iTOL-102, a potential T1D cure combining stem cell-derived pancreatic islets with an immunomodulator, without requiring lifelong immune suppression.
In February 2025, COUR Pharmaceuticals announced FDA clearance of its IND application for CNP-103, a nanoparticle therapy targeting the underlying autoimmunity of Type 1 Diabetes.
In January 2025, Rise Therapeutics announced FDA acceptance of its IND application to begin a Phase 1 trial for R-5780, with ongoing studies also focused on ulcerative colitis, rheumatoid arthritis, and Type 1 Diabetes.
Strategic collaborations between biotechnology companies, pharmaceutical organizations, and academic institutions continue to accelerate the development and commercialization of novel T1DM therapies.
Growth in the weekly insulin segment and the broader disease-modifying therapy market is expected to drive future innovation across the 7MM.
Discover key developments and opportunities in the Type 1 Diabetes Market @ Type 1 Diabetes Market Size – https://www.delveinsight.com/sample-request/type-1-diabetes-market
Type 1 Diabetes Market Outlook
The Type 1 Diabetes market is experiencing significant evolution as healthcare systems and pharmaceutical companies increasingly invest in therapies that go beyond symptom management to address the autoimmune origin of the disease. Advances in disease-modifying agents, weekly insulin formulations, beta cell preservation strategies, and antigen-specific tolerance induction are substantially improving the therapeutic outlook for T1DM patients.
The market is also benefiting from expanding applications in early disease interception, adjunct therapy to insulin, and novel drug delivery technologies including continuous glucose monitoring and closed-loop insulin delivery systems. Growing investments, strategic partnerships, and regulatory support are expected to further accelerate innovation and commercialization.
As precision medicine continues to gain momentum in diabetes management, Type 1 Diabetes therapies are positioned to become increasingly personalized and effective, enabling earlier intervention, improved patient outcomes, and more comprehensive disease management across all seven major markets.
Scope of the Type 1 Diabetes Market Report
Study Period: 2020–2034
Forecast Period: 2024–2034
Geographies Covered: The US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan
Market Size by 2034: USD XX Million
Major Type 1 Diabetes Companies: Eli Lilly and Company, Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, and others.
Market Segments Covered: Type 1 Diabetes Diagnosed Prevalent Cases, Age-Wise Prevalent Cases, Total Treated Cases, Market Size by Therapies, and Market Size by Class.
Competitive Intelligence Analysis: Market trends, competitive landscape, strategic collaborations, acquisitions, investments, regulatory approvals, and emerging therapies.
Key Focus Areas: Disease-Modifying Therapies, Weekly Insulin Formulations, Beta Cell Preservation, Antigen-Specific Immune Tolerance, Continuous Glucose Monitoring, and Anti-CD3 Monoclonal Antibody Applications.
Table of Contents
Key Insights
Report Introduction
Type 1 Diabetes Mellitus (T1DM) Market Overview at a Glance
Executive Summary of Type 1 Diabetes Mellitus (T1DM)
Key Events
Epidemiology and Market Methodology
Disease Background and Overview
Epidemiology and Patient Population
Patient Journey
Key Endpoints in Type 1 Diabetes Mellitus (T1DM) Clinical Trials
Marketed Therapies
Emerging Therapies
Type 1 Diabetes Mellitus: 7 Major Market Analysis
Treatment Course Cost
Market Access and Reimbursement
KOL Views
SWOT Analysis
Unmet Needs
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
How DelveInsight’s Type 1 Diabetes Market Report Helps CXOs and Business Leaders
Evaluate the current and future market opportunity across key regions, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, through detailed market forecasts, epidemiology assessments, and growth trend analysis.
Benchmark leading Type 1 Diabetes therapies, products, and treatment platforms through comprehensive competitive intelligence, company profiling, pipeline evaluation, and innovation tracking.
Identify potential licensing, acquisition, co-development, and strategic partnership opportunities by monitoring emerging market participants, novel therapeutic mechanisms, and recent industry collaborations, mergers, and investments.
Assess the impact of upcoming regulatory approvals, technological advancements, reimbursement developments, and product launches on market share, pricing strategies, adoption rates, and commercial success.
Support strategic decision-making with insights into key opinion leader (KOL) perspectives, unmet treatment needs, clinical adoption trends, therapy utilization, patient stratification approaches, and evolving market dynamics within the Type 1 Diabetes landscape.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Abhishek kumarEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/type-1-diabetes-market
